Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
September 30 2022 - 06:24AM
Edgar (US Regulatory)
FORM
6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report
of Foreign Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of September 2022
Commission File
Number: 001-11960
AstraZeneca
PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge CB2
0AA
United
Kingdom
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number assigned to the
Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca
PLC
INDEX
TO EXHIBITS
1.
Board
Committee Changes
30
September 2022 10:30 BST
Remuneration Committee Chair Appointment
AstraZeneca
PLC today announced the appointment of Sheri McCoy, Non-Executive
Director, as Chair of the Remuneration Committee. Sheri has
served as a member of the Remuneration Committee since July
2018.
Sheri
will succeed Michel Demaré who will step down as Chair of the
Remuneration Committee following his recent appointment as
Chair-designate of the Board. He will remain a member of the
Committee.
Sheri
will also become a member of the Nomination and Governance
Committee.
These
Remuneration Committee and Nomination and Governance Committee
changes are effective from 1 December 2022. As previously
announced, Michel Demaré will become Chair of the Board at the end
of the Company's Annual General Meeting in April 2023.
Notes
Biography
and photograph:
https://www.astrazeneca.com/our-company/leadership.html#board
AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global,
science-led biopharmaceutical company that focuses on the
discovery, development, and commercialisation of prescription
medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory
& Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For details on how to contact the Investor
Relations Team, please click here.
For Media contacts, click here.
Adrian Kemp
Company Secretary
AstraZeneca PLC
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
30 September 2022
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Dec 2022 to Jan 2023
AstraZeneca (NYSE:AZN)
Historical Stock Chart
From Jan 2022 to Jan 2023
